```
=> s (emulsion? or liposome?)(p)(fenofibrate or fibrate)

        117822 EMULSION?
          8913 LIPOSOME?
            90 FENOFIBRATE
            31 FIBRATE
L1           5 (EMULSION? OR LIPOSOME?)(P)(FENOFIBRATE OR FIBRATE)

=> d 1-5


1.  5,700,471, Dec. 23, 1997, Production of fine particle dye or
drug
preparations; Lutz End, et al., 424/400; 8/526; 34/372; 252/363.5
[IMAGE
AVAILABLE]

2.  4,714,789, Dec. 22, 1987, Halo-biphenyl tertiary alcohols
useful in
therapy in the treatment of atherosclerosis; Henri Cousse, et al.,
568/807 [IMAGE AVAILABLE]

3.  4,452,797, Jun. 5, 1984, 3-Aminosydnonimines compounds and
their use;
Karl Schonafinger, et al., 514/252; 544/58.2, 60, 366, 367 [IMAGE
AVAILABLE]

4.  4,332,801, Jun. 1, 1982, 3-Aminosydnonimines, their
preparation and
use; Karl Schonafinger, et al., 514/227.8; 544/58.7, 60 [IMAGE
AVAILABLE]

5.  4,305,939, Dec. 15, 1981, 3-Aminosydnonimines, their
preparation and
use; Karl Schonafinger, et al., 514/227.8; 544/58.2, 58.7, 60, 367
[IMAGE
AVAILABLE]

=> d 1-5 kwic


US PAT NO:     5,700,471 [IMAGE AVAILABLE]            L1: 1 of 5

DETDESC:

DETD(1)

 The . . . advantage of reduced costs but also makes it
possible for
```

the first time to produce stable nano-particles, for example of **fenofibrate**, because when solid particles are produced via aqueous dispersions they immediately grow, by Ostwaldt ripening, into larger particles and thus the result of the micronization is nullified. Ostwaldt ripening is not observed with the **emulsions** which are produced briefly as intermediates in this process. It is additionally slowed down by the complete or substantial avoidance. . .

DETDESC:

DETD(2)

However, . . . substances which are not amenable to processing entirely without solvents because their aqueous dispersions agglomerate and therefore cannot be metered. **Fenofibrate** is one example of this. Substances of this type are therefore, according to the invention, not dispersed in water but. . . suspension, and the remainder of the process is carried out as described previously, ie. immediate spray drying of the melt **emulsion** or rapid cooling of the resulting fine-particle **emulsion** and, where appropriate, dehydration and drying of the resulting suspension. The rapid cooling can expediently be achieved by adding cold. . .

DETDESC:

DETD(26)

Production of a micronisate of **fenofibrate** from an **emulsion** with a solids content of 30%

DETDESC:

DETD(32)

The . . . exchanger (6) at 130.degree. C. The temperature of the mixture reached 92.degree. C., which is above the melting point of **fenofibrate** (80.degree. C.). The resulting **emulsion** was discharged through the pressure-limiting valve (8), conveyed through the heated tube (9) directly into the spray tower (10) and. . . of 80.degree. C. This resulted in a free-flowing powder (11) which on dispersion in water afforded a colloidal dispersion of **fenofibrate** with a particle size of 0.66 .mu.m (volume average, determined by laser diffraction).

US PAT NO: 4,714,789 [IMAGE AVAILABLE] L1: 2 of 5

DETDESC:

DETD(62)

On . . . form of tablets, pills, capsules, or the like, or liquid
form, for example, in the form of solutions, suspensions, or **emulsions**. Alternatively, the pharmaceutical preparations may be made
available in a form suitable for injection by subjecting the same to
conventional. . . g to 1 mg/kg of body weight and which approximate or
are somewhat lower than those usual for Clofibrate and/or **Fenofibrate**
may be employed. The pharmaceutical compositions of the invention can be
used in human or veterinary medicine where indicated, for. . .

US PAT NO: 4,452,797 [IMAGE AVAILABLE] L1: 3 of 5

SUMMARY:

BSUM(55)

For . . . suitable for enteral or parenteral administration. Appropriate pharmaceutical formulations are, for example, tablets, sugar-coated tablets, pills, capsules, solutions, suspensions or **emulsions** which, in addition to an effective amount of an active compound of formula I or an acid-addition salt thereof, comprise. . .
prazosin, clonidine and Rauwolfia alkaloids), agents which lower the
level of fatty acid in the blood (such as bezafibrate and **fenofibrate**) and agents for the prophylaxis of thrombosis (such as phenprocoumon).

US PAT NO: 4,332,801 [IMAGE AVAILABLE] L1: 4 of 5

SUMMARY:

BSUM(60)

For . . . suitable for enteral or parenteral administration. Appropriate pharmaceutical formulations are, for example, tablets, sugar-coated tablets, pills, capsules, solutions, suspensions or **emulsions** which, in addition to an effective amount of an active compound of formula I or an acid-addition salt thereof, comprise. . .
prazosin, clonidine and Rauwolfia alkaloids), agents which lower the
level of fatty acid in the blood (such as bezafibrate and **fenofibrate**) and agents for the prophylaxis of thrombosis (such as phenprocoumon).

US PAT NO: 4,305,939 [IMAGE AVAILABLE] L1: 5 of 5

SUMMARY:

BSUM(60)

For . . . suitable for enteral or parenteral administration. Appropriate pharmaceutical formulations are, for example, tablets, sugar-coated tablets, pills, capsules, solutions, suspensions or **emulsions** which, in addition to an effective amount of an active compound of formula I or an acid-addition salt thereof, comprise. . .
prazosin, clonidine and Rauwolfia alkaloids), agents which lower the
level of fatty acid in the blood (such as bezafibrate and **fenofibrate**) and agents for the prophylaxis of thrombosis (such as phenprocoumon).

=> s (emulsion? or liposome? and (fenofibrate or fibrate)

UNMATCHED LEFT PARENTHESIS '(EMULSION?'

=> s (emulsion? or liposome?) and (fenofibrate or fibrate)

```
        117822 EMULSION?
          8913 LIPOSOME?
            90 FENOFIBRATE
            31 FIBRATE
L2          55 (EMULSION? OR LIPOSOME?) AND (FENOFIBRATE OR
FIBRATE)
```

=> d 1-55

1. 5,859,051, Jan. 12, 1999, Antidiabetic agents; Alan D. Adams, et al.,
514/469, 307, 415, 457; 546/146; 548/469; 549/283, 462 [IMAGE AVAILABLE]

2. 5,856,503, Jan. 5, 1999, Aminoalkyl-substituted benzo-heterocyclic
compounds; Johannes Aebi, et al., 548/207; 544/49, 63, 235; 546/149, 150,
152, 165; 548/241; 549/32, 462, 469 [IMAGE AVAILABLE]

3. 5,847,008, Dec. 8, 1998, Method of treating diabetes and related
disease states; Thomas W. Doebber, et al., 514/708, 706, 866, 909, 910
[IMAGE AVAILABLE]

4. 5,821,264, Oct. 13, 1998, Tocotrienols and tocotrienol-like compounds
and methods for their use; Ronald H. Lane, et al., 514/458; 549/398, 401,
404, 405, 408, 409 [IMAGE AVAILABLE]

5. 5,795,909, Aug. 18, 1998, DHA-pharmaceutical agent conjugates of
taxanes; Victor E. Shashoua, et al., 514/449, 549 [IMAGE AVAILABLE]

6. 5,747,528, May 5, 1998, Chroman derivatives as anti-oxidants; Bharat
Kakidas Trivedi, 514/456, 233.5; 544/151; 549/407 [IMAGE AVAILABLE]

7. 5,719,197, Feb. 17, 1998, Compositions and methods for topical administration of pharmaceutically active agents; David P. Kanios, et
al., 514/772.6; 424/435, 443; 514/781, 782 [IMAGE AVAILABLE]

8. 5,700,471, Dec. 23, 1997, Production of fine particle dye or drug
preparations; Lutz End, et al., 424/400; 8/526; 34/372; 252/363.5 [IMAGE
AVAILABLE]

9. 5,698,527, Dec. 16, 1997, Steroidal glycosides as antihyperlipidemic
agents; Dooseop Kim, 514/26; 536/5 [IMAGE AVAILABLE]

10. 5,679,704, Oct. 21, 1997, Use of 2- (N-(2-aminoethyl)amino) acetic
acid derivatives; Karl Schonafinger, et al., 514/438, 397, 401, 408, 439,
461, 564 [IMAGE AVAILABLE]

11. 5,668,117, Sep. 16, 1997, Methods of treating neurological diseases
and etiologically related symptomology using carbonyl trapping agents in
combination with previously known medicaments; Howard K. Shapiro, 514/55;
436/74, 518; 514/1, 23, 54, 811, 866, 878, 879, 903, 912; 536/1.11, 20
[IMAGE AVAILABLE]

12. 5,658,944, Aug. 19, 1997, Anti-atherosclerotic aryl compounds; James
Mood Chapman, Jr., et al., 514/478, 534, 535, 576, 588, 617, 619; 560/34,
39, 43, 61; 562/439, 444, 457, 471; 564/48, 161, 163, 169 [IMAGE AVAILABLE]

13. 5,645,856, Jul. 8, 1997, Delivery systems for hydrophobic drugs;
Jonathan Ernest Lacy, et al., 424/455, 456; 514/784, 785, 786, 937, 975
[IMAGE AVAILABLE]

14. 5,591,772, Jan. 7, 1997, Tocotrienols and tocotrienol-like compounds
and methods for their use; Ronald H. Lane, et al., 514/458; 549/401, 408
[IMAGE AVAILABLE]

15. 5,554,611, Sep. 10, 1996, Use of coumarin derivatives; Karl Sch

onafinger, et al., 514/228.2, 233.5, 255, 318, 320, 337, 385, 422, 457
[IMAGE AVAILABLE]

16. 5,500,436, Mar. 19, 1996, 2-(N-(2-aminomethyl)amino)acetic acid
derivatives to inhibit advanced glycosylation; Karl Schonafinger, et al.,
514/397, 401, 408, 438, 439, 461, 564 [IMAGE AVAILABLE]

17. 5,486,531, Jan. 23, 1996, Hydroxymethylfurazancarboxylic acid
derivatives; Karl Schonafinger, et al., 514/364, 340; 546/209, 269.1;
548/125 [IMAGE AVAILABLE]

18. 5,466,687, Nov. 14, 1995, Arylidene-1-azacycloalkanes and
arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these
compounds and their use, and processes for their preparation; Roland
Maier, et al., 514/212, 226.8, 228.8, 326, 372, 374, 385, 399; 540/598,
601, 603; 544/54, 96, 335; 546/209, 210; 548/146, 238, 314.7 [IMAGE AVAILABLE]

19. 5,455,273, Oct. 3, 1995, N,N-disubstituted arylcycloalkylamines, the
salts thereof, pharmaceutical compositions containing these compounds and
the use thereof and processes for preparing them; Roland Maier, et al.,
514/617, 438, 448, 510, 521, 523, 529, 530, 531, 534, 535, 538, 539, 542,
546, 549, 601, 602, 604, 605, 613, 616, 624, 627, 629 [IMAGE AVAILABLE]

20. 5,446,070, Aug. 29, 1995, Compositions and methods for topical
administration of pharmaceutically active agents; Juan A. Mantelle,
514/772.6; 424/485, 486, 487, 488; 514/781, 782 [IMAGE AVAILABLE]

21. 5,424,326, Jun. 13, 1995, Phenyl-1,2,5-oxadiazolecarboxamide-2-
oxides, their preparation and their use; Karl Schonafinger, et al.,
514/364, 252, 256, 340; 540/524; 544/333, 367; 546/209, 269.1; 548/125
[IMAGE AVAILABLE]

22. 5,424,303, Jun. 13, 1995, Substituted aminophosphonate derivatives,
process for their preparation and pharmaceutical compositions containing
them; Hieu T. Phan, et al., 514/89; 546/22, 24; 548/113, 115, 413;
549/220, 221; 558/166, 168, 169, 190 [IMAGE AVAILABLE]

23. 5,422,373, Jun. 6, 1995, Anti-atherosclerotic aryl compounds; Karl
W. Franzmann, 514/598, 467, 507, 596, 622, 824; 549/449; 560/29; 564/48,

52, 170 [IMAGE AVAILABLE]

24. 5,399,569, Mar. 21, 1995, Salts of 3-(cis-2,6-dimethylpiperidino) sydnone imine; Karl Schonafinger, et al., 514/326, 318; 546/209; 548/125 [IMAGE AVAILABLE]

25. 5,374,640, Dec. 20, 1994, Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxides; Karl Schonafinger, et al., 514/340; 546/269.4 [IMAGE AVAILABLE]

26. 5,360,812, Nov. 1, 1994, Fused 1,2,5-oxadiazole-2-oxides and their use; Joachim Brendel, et al., 514/364; 546/116; 548/126 [IMAGE AVAILABLE]

27. 5,280,119, Jan. 18, 1994, Heterocyclic amine-boranes, and method of inhibiting DNA topoisomerase activity and/or combatting inflammation, hyperlipidemia, and/or neoplasia using amine-borane compounds; Bernard F. Spielvogel, et al., 544/229; 546/13; 548/110, 405 [IMAGE AVAILABLE]

28. 5,221,680, Jun. 22, 1993, Substituted 3-aminosydnonimines; Karl Schonafinger, et al., 514/326, 318; 544/58.2, 60, 138, 367; 546/193, 209; 548/125 [IMAGE AVAILABLE]

29. 5,204,475, Apr. 20, 1993, Substituted 3-aminosydnone imines and salts thereof; Karl Schonafinger, et al., 546/210; 548/125; 549/207 [IMAGE AVAILABLE]

30. 5,179,206, Jan. 12, 1993, Substituted 3-aminosydnone imines; Eckard Kujath, et al., 546/209 [IMAGE AVAILABLE]

31. 5,167,964, Dec. 1, 1992, Semi-enteric drug delivery systems and methods for preparing same; Nouman Muhammad, et al., 424/482, 78.24, 440, 441, 472, 480, 494, 495, 497 [IMAGE AVAILABLE]

32. 5,166,166, Nov. 24, 1992, 3-dicyclohexylaminosydnone imines, process for their preparation and their use; Karl Schonafinger, et al., 514/364; 548/125 [IMAGE AVAILABLE]

33. 5,155,109, Oct. 13, 1992, 3-piperazinosydnone imines, process for their preparation and their use; Karl Schonafinger, et al., 514/252;

544/367 [IMAGE AVAILABLE]

34. 5,128,331, Jul. 7, 1992, Method for lowering plasma lipid levels or
blood pressure; Lan Nguyen, et al., 514/101, 107, 824 [IMAGE AVAILABLE]

35. 5,120,732, Jun. 9, 1992, Substituted 3-aminosyndone imines, a process for their preparation and their use; Karl Schonafinger, et al.,
514/236.2, 227.8, 255, 319, 325, 326, 364; 544/60, 138, 367; 546/195,
203, 209; 548/125 [IMAGE AVAILABLE]

36. 5,079,244, Jan. 7, 1992, Substituted 3-aminosydnone imines, pharmaceutical compositions containing same, and process for administering same; Eckard Kujath, et al., 514/227.8, 236.2, 252, 326,
364; 544/60, 138, 367; 548/125 [IMAGE AVAILABLE]

37. 5,043,330, Aug. 27, 1991, Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them; Lan Nguyen, et al., 514/107; 558/77, 83,
161; 562/19, 21 [IMAGE AVAILABLE]

38. 5,006,540, Apr. 9, 1991, Substituted 3-aminosydnonimines, processes
for their preparation and their use; Karl Schonafinger, et al., 514/361;
548/125 [IMAGE AVAILABLE]

39. 4,946,866, Aug. 7, 1990, Use of oxirancarboxylic acids for the treatment of hyperlipemia; Horst Wolf, et al., 514/475, 824 [IMAGE AVAILABLE]

40. 4,937,244, Jun. 26, 1990, Substituted 3-aminosydnonimines, processes
for their preparation and their use; Karl Schonafinger, et al., 514/252,
227.8, 236.2, 326, 364; 544/60, 138, 367; 546/209; 548/125 [IMAGE AVAILABLE]

41. 4,937,241, Jun. 26, 1990, N-substituted N-nitrosoaminoacetonitriles,
process for their preparation and their use; Karl Schonafinger, et al.,
514/227.5; 544/58.1, 58.2 [IMAGE AVAILABLE]

42. 4,888,333, Dec. 19, 1989, Allymercaptoacetylsydnonimines, processes
for their preparation, and their use; Helmut Bohn, et al., 514/212, 227.8, 236.2, 252, 326, 364; 540/524; 544/60, 138, 367; 546/209; 548/125
[IMAGE AVAILABLE]

43. 4,859,703, Aug. 22, 1989, Lipid regulating compositions; Brian R.

Krause, 514/543; 260/DIG.47; 514/537, 563, 571, 627, 824 [IMAGE AVAILABLE]

44. 4,845,091, Jul. 4, 1989, Substituted 3-amino-sydnonimines, their use
and pharmaceutical products containing them; Karl Schonafinger, et al.,
514/212, 227.8, 236.5, 252, 326, 364; 540/603; 544/58.2, 58.7, 367; 546/210; 548/125 [IMAGE AVAILABLE]

45. 4,719,209, Jan. 12, 1988, Antiatherosclerotic agent compositions;
Tadashi Sasaki, et al., 514/223.8 [IMAGE AVAILABLE]

46. 4,714,789, Dec. 22, 1987, Halo-biphenyl tertiary alcohols useful in
therapy in the treatment of atherosclerosis; Henri Cousse, et al., 568/807 [IMAGE AVAILABLE]

47. 4,681,891, Jul. 21, 1987, Dihydro-2,6-dimethyl pyridines, formulations and method of use for treating angina pectoris, high blood
pressure or disturbances of cerebral or peripheral blood flow; Karl Schonafinger, et al., 514/340, 342; 546/251, 256, 268.7, 269.4, 270.4
[IMAGE AVAILABLE]

48. 4,610,984, Sep. 9, 1986, Substituted piperazin-1-yl-acetic acid
amides; Karl Schonafinger, et al., 514/212, 235.8, 255; 544/121, 357,
359, 360, 372, 379, 386 [IMAGE AVAILABLE]

49. 4,558,058, Dec. 10, 1985, Substituted 1,4-dihydropyridines and their
use as medicaments; Karl Schonafinger, et al., 514/342, 333, 340; 546/256, 257, 258, 268.4, 268.7, 269.4, 270.4, 271.4, 272.4, 274.1 [IMAGE
AVAILABLE]

50. 4,551,454, Nov. 5, 1985, 3-(4-Alkoxycarbonylpiperazin-1-yl)-sydnonimines, a process for their preparation and use; Karl Schonafinger,
et al., 514/252; 544/367 [IMAGE AVAILABLE]

51. 4,452,797, Jun. 5, 1984, 3-Aminosydnonimines compounds and their
use; Karl Schonafinger, et al., 514/252; 544/58.2, 60, 366, 367 [IMAGE
AVAILABLE]

52. 4,436,743, Mar. 13, 1984, 3-[N-(Lower alkyl)-N-(tetrahydro-3-thienyl
5,5-dioxide)]sydnonimines; Karl Schonafinger, et al., 514/364, 252; 544/367; 548/125 [IMAGE AVAILABLE]

53. 4,356,178, Oct. 26, 1982,
3,4-(Bis-substituted)-1,2,5-oxdiazole

2-oxides, their use and pharmaceutical formulations containing them; Karl Schonafinger, et al., 514/212, 232.2, 316, 326, 364; 540/603; 544/82, 138, 357, 367; 546/187, 209; 548/125 [IMAGE AVAILABLE]

54. 4,332,801, Jun. 1, 1982, 3-Aminosydnonimines, their preparation and use; Karl Schonafinger, et al., 514/227.8; 544/58.7, 60 [IMAGE AVAILABLE]

55. 4,305,939, Dec. 15, 1981, 3-Aminosydnonimines, their preparation and use; Karl Schonafinger, et al., 514/227.8; 544/58.2, 58.7, 60, 367 [IMAGE AVAILABLE]

```
file epo

FILE 'EPO' ENTERED AT 10:25:54 ON 08 APR 1999

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *                          G  P  I                                *
  *     E U R O P E A N   P A T E N T   A B S T R A C T S          *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *


=> s (emulsion? or liposome?) and (fenofibrate or fibrate)

         18282 EMULSION?
          1263 LIPOSOME?
            13 FENOFIBRATE
             3 FIBRATE
L3           0 (EMULSION? OR LIPOSOME?) AND (FENOFIBRATE OR
FIBRATE)

=> file jop

'JOP' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'EPO'

=> file jpo

FILE 'JPO' ENTERED AT 10:26:44 ON 08 APR 1999

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *                          G  P  I                                *
  *     J A P A N E S E   P A T E N T   A B S T R A C T S          *
  *                                                                 *
  *     THE FILE IS CURRENT THROUGH DECEMBER 31, 1998.              *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *


=> s (emulsion? or liposome?) and (fenofibrate or fibrate)

         33497 EMULSION?
           697 LIPOSOME?
             1 FENOFIBRATE
             4 FIBRATE
L4           0 (EMULSION? OR LIPOSOME?) AND (FENOFIBRATE OR
FIBRATE)
```